Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial

Date

08 Oct 2016

Session

Poster Display

Presenters

Stefan Kasper

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

S. Kasper1, J. Meiler1, H. Knipp2, T. Höhler3, P. Reimer4, H..T. Steinmetz5, W. Berger6, G. Linden1, S. Ting7, P. Markus8, A. Paul9, A. Dechêne10, B. Schumacher11, K. Kostbade1, K. Worm7, K.W. Schmid7, T. Herold7, M. Schuler1, T. Trarbach12

Author affiliations

  • 1 Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 2 Department Of Medicine I, Alfried Krupp Krankenhaus, Essen/DE
  • 3 Medizinische Klinik I, Prosper Hospital, 45659 - Recklinghausen/DE
  • 4 Department For Hematology/oncology And Stem Cell, Kliniken Essen Süd Evangelisches Krankenhaus Essen, 45239 - Essen/DE
  • 5 Medical Oncology, Praxis fuer Haematologie und Onkologie, 50677 - Köln/DE
  • 6 Hematology/oncology, Marienhospital - Onkologisches Zentrum Essen Nord, 45239 - Essen/DE
  • 7 Institute Of Pathology, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 8 Department Of General, Visceral And Trauma Surgery, Elisabeth Hospital Essen, Essen/DE
  • 9 Department Of General, Visceral And Transplantation Surgery, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 10 Department Of Gastroenterology And Hepatology, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 11 Department Of Gastroenterology, Elisabeth Hospital Essen, Essen/DE
  • 12 Center For Tumor Biology And Integrative Medicine, Hospital Wilhelmshaven, Wilhelmshaven/DE
More

Resources

Background

The multicenter, single-arm, phase II trial (Simon's two stage design) evaluated the efficacy of mFOLFOX6 + cetuximab (500 mg/m2) q2w as 1st line therapy in KRAS wt mCRC. Final extended molecular and subgroup analyses are presented.

Methods

Primary endpoint was response rate (ORR) per RECIST 1.0. In stage 1 and 2, 13 and 25 responders were needed in 37 and 53 pts, respectively, to further evaluate this therapy (H1 p > 0.55). Secondary endpoints were PFS, OS, safety, metastasectomy and quality of life (QoL). Extended molecular profiling was performed using NGS-based panel sequencing including NRAS, KRAS, BRAF, PIK3CA and TP53. Clinical parameters included: tumor location (left-sided LCRC), early tumor-shrinkage (ETS), depth of response (DPR), metastasectomy and inflammation markers (neutrophil/lymphocyte ratio-NLR). Differences in ORR, PFS and OS were calculated using chi-square and log rank tests. Hazard ratios were calculated by Cox regression analysis.

Results

The primary endpoint was met with 57 pts enrolled (ITT) and 53 pts evaluable for response. There were 26 responders in stage 1 (70%) and 38 responders in the ITT (ORR of 67%). Median PFS and OS were 9.6 (7.4-11.7) and 29.4 (19.3-39.5) months, respectively. Secondary metastasectomy was achieved in 31.7%. Grade 3/4 AEs occurred in 52%, including leukocytopenia, rash and GI-toxicity. Molecular profiling could be performed in 44 pts (77%). Additional RAS or BRAF mutations were detected in 17.8% and 10.6%, respectively, with a negative impact on outcomes. TP53 mutations were detected in 62.5% without impact on outcomes. Pts with LCRC, ETS or metastasectomy had significantly prolonged OS, whereas pts with high NLR (>5) had inferior OS (all p-values

Conclusions

This study supports the efficacy and safety of q2w cetuximab given in combination with mFOLFOX6. Extended mutational analyses of key oncogenes and routinely assessed clinical parameters may help to identify patients with maximum likelihood of benefit from cetuximab-based chemotherapy.

Clinical trial identification

Clinical trial information: NCT01051167

Legal entity responsible for the study

University Hospital Essen

Funding

Merck, Sanofi

Disclosure

S. Kasper: Merck: Research grant Merck, Sanofi, Amgen, Lilly: scientific talks Merck, Sanofi, Amgen, Lilly, BMS, MSD, Roche, Bayer: Adboards. J. Meiler: Sanofi, Amgen:Scientific talk Lilly, Pfizer, BMS, Sanofi: Adboard Bayer: Meeting invitation. M. Schuler: AstraZeneca,, Alexion, Boehringer Ingelheim, BMS, Celgene, GSK, IQWig, Lilly, Novartis Pfizer: Advisory Boards, Honoraria, Research Funding, Travel University Duisburg-Essen: Patent T. Trarbach: Merck, Sanofi und Amgen: Advisory Boards, travel grants, research grants. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings